Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2015

Open Access 01-11-2015 | Review

Relationship Between Cytomegalovirus Infection and Steroid Resistance in Inflammatory Bowel Disease: A Meta-Analysis

Authors: Xiao-wei Wu, Lin Wu, Hong-zan Ji, Fang-yu Wang

Published in: Digestive Diseases and Sciences | Issue 11/2015

Login to get access

Abstract

Background and Aims

Steroid resistance presents an administration difficulty in inflammatory bowel disease (IBD). The reason of steroid resistance is still unclear, but cytomegalovirus (CMV) infection may be a potential cause in some IBD patients. We carried out a meta-analysis to investigate the relationship between CMV infection and steroid-resistant IBD.

Methods

The PubMed, EMBASE, and Cochrane Library databases were searched up to June 2014, with no language restrictions, for observational studies. Additional references were obtained from reviewed articles.

Results

Eleven studies involving 867 IBD patients were included in the meta-analysis. Steroid resistance rate was 70.0 % in CMV-positive IBD patients, which was significantly higher than that in CMV-negative IBD patients (RR = 2.12, 95 % CI = 1.72–2.61). There was significant heterogeneity in the included eleven studies (I 2 = 57.6 %). When the only one study with a few patients was excluded, sensitivity analysis suggested a similar outcome (RR = 2.07, 95 % CI = 1.80–2.39, 10 studies). Based on the funnel plot and Egger’s test, we considered that there was a probable publication bias.

Conclusion

Our meta-analysis suggests that CMV-positive IBD patients have a nearly double risk of steroid resistance compared with CMV-negative IBD patients, indicating that CMV infection is a probable cause of steroid-resistant IBD.
Literature
2.
go back to reference Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670–1689.CrossRefPubMed Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670–1689.CrossRefPubMed
3.
go back to reference Larson DW, Pemberton JH. Current concepts and controversies in surgery for IBD. Gastroenterology. 2004;126:1611–1619.CrossRefPubMed Larson DW, Pemberton JH. Current concepts and controversies in surgery for IBD. Gastroenterology. 2004;126:1611–1619.CrossRefPubMed
5.
go back to reference Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68:1157–1167.CrossRefPubMed Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68:1157–1167.CrossRefPubMed
7.
8.
go back to reference Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.CrossRefPubMed Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.CrossRefPubMed
9.
go back to reference Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155–1160.CrossRefPubMed Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155–1160.CrossRefPubMed
10.
go back to reference Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: is there a link? World J Gastroenterol. 2006;12:4813–4818.PubMedCentralPubMed Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: is there a link? World J Gastroenterol. 2006;12:4813–4818.PubMedCentralPubMed
11.
go back to reference Maconi G, Lombardini M, Furfaro F, Bezzio C, Zerbi P, Ardizzone S. Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment. Eur J Gastroenterol Hepatol. 2014;26:1146–1151.CrossRefPubMed Maconi G, Lombardini M, Furfaro F, Bezzio C, Zerbi P, Ardizzone S. Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment. Eur J Gastroenterol Hepatol. 2014;26:1146–1151.CrossRefPubMed
12.
go back to reference Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012;46:51–56.CrossRefPubMed Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012;46:51–56.CrossRefPubMed
13.
go back to reference Matsuoka K, Iwao Y, Mori T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007;102:331–337.CrossRefPubMed Matsuoka K, Iwao Y, Mori T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007;102:331–337.CrossRefPubMed
14.
go back to reference Zeki SS, Kodati S, Jordan A, Hansi N, Thomas-Gibson S, Nightingale JM. Colectomy rates for patients treated for CMV disease in the context of ulcerative colitis do not differ from those who are not treated for CMV disease. Gastroenterology. 2010;138:S537.CrossRef Zeki SS, Kodati S, Jordan A, Hansi N, Thomas-Gibson S, Nightingale JM. Colectomy rates for patients treated for CMV disease in the context of ulcerative colitis do not differ from those who are not treated for CMV disease. Gastroenterology. 2010;138:S537.CrossRef
15.
go back to reference Delvincourt M, Lopez A, Pillet S, et al. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:712–720.CrossRefPubMed Delvincourt M, Lopez A, Pillet S, et al. The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:712–720.CrossRefPubMed
18.
go back to reference Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46:S59–S65.CrossRefPubMed Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46:S59–S65.CrossRefPubMed
19.
go back to reference Criscuoli V, Casa A, Orlando A, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis. 2004;36:818–820.CrossRefPubMed Criscuoli V, Casa A, Orlando A, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis. 2004;36:818–820.CrossRefPubMed
20.
go back to reference Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28:365–373.CrossRefPubMed Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28:365–373.CrossRefPubMed
21.
go back to reference Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005;37:418–423.CrossRefPubMed Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005;37:418–423.CrossRefPubMed
22.
go back to reference Kuwabara A, Okamoto H, Suda T, Ajioka Y, Hatakeyama K. Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 2007;42:823–829.CrossRefPubMed Kuwabara A, Okamoto H, Suda T, Ajioka Y, Hatakeyama K. Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 2007;42:823–829.CrossRefPubMed
23.
go back to reference Li TT, Lv ZS, Wang BM, Zhang J. Relationship between refractory ulcerative colitis and cytomegalovirus infection. World Chin J Dig. 2010;18:1174–1177. Li TT, Lv ZS, Wang BM, Zhang J. Relationship between refractory ulcerative colitis and cytomegalovirus infection. World Chin J Dig. 2010;18:1174–1177.
24.
go back to reference Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci. 2009;54:2456–2462.CrossRefPubMed Maher MM, Nassar MI. Acute cytomegalovirus infection is a risk factor in refractory and complicated inflammatory bowel disease. Dig Dis Sci. 2009;54:2456–2462.CrossRefPubMed
25.
go back to reference Criscuoli V, Rizzuto MR, Montalbano L, Gallo E, Cottone M. Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis. World J Gastroenterol. 2011;17:633–638.PubMedCentralCrossRefPubMed Criscuoli V, Rizzuto MR, Montalbano L, Gallo E, Cottone M. Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis. World J Gastroenterol. 2011;17:633–638.PubMedCentralCrossRefPubMed
26.
go back to reference Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001–2008.CrossRefPubMed Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001–2008.CrossRefPubMed
27.
go back to reference McCurdy JD, Jones A, Enders FT, et al. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:131–137.CrossRefPubMed McCurdy JD, Jones A, Enders FT, et al. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:131–137.CrossRefPubMed
28.
go back to reference Powell RD, Warner NE, Levine RS, Kirsner JB. Cytomegalic inclusion disease and ulcerative colitis; report of a case in a young adult. Am J Med. 1961;30:334–340.CrossRefPubMed Powell RD, Warner NE, Levine RS, Kirsner JB. Cytomegalic inclusion disease and ulcerative colitis; report of a case in a young adult. Am J Med. 1961;30:334–340.CrossRefPubMed
29.
go back to reference Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620–1627.CrossRefPubMed Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620–1627.CrossRefPubMed
30.
go back to reference Kim YS, Kim YH, Kim JS, et al. Cytomegalovirus infection in patients with new onset ulcerative colitis: a prospective study. Hepatogastroenterology. 2012;59:1098–1101.PubMed Kim YS, Kim YH, Kim JS, et al. Cytomegalovirus infection in patients with new onset ulcerative colitis: a prospective study. Hepatogastroenterology. 2012;59:1098–1101.PubMed
31.
go back to reference Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis. 2009;3:141–148.CrossRefPubMed Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohns Colitis. 2009;3:141–148.CrossRefPubMed
32.
go back to reference Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10:245–250.CrossRefPubMed Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10:245–250.CrossRefPubMed
33.
go back to reference Galiatsatos P, Shrier I, Lamoureux E, Szilagyi A. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. Dig Dis Sci. 2005;50:609–616.CrossRefPubMed Galiatsatos P, Shrier I, Lamoureux E, Szilagyi A. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. Dig Dis Sci. 2005;50:609–616.CrossRefPubMed
34.
go back to reference van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4+ CD28− granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol. 2004;173:1834–1841.CrossRefPubMed van Leeuwen EM, Remmerswaal EB, Vossen MT, et al. Emergence of a CD4+ CD28− granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol. 2004;173:1834–1841.CrossRefPubMed
35.
go back to reference Yi HA, Kim MS, Jang SY, Lee YM, Ahn JH, Lee CH. Cellular signals involved in cyclooxygenase-2 expression induced by human cytomegalovirus. Virus Res. 2009;146:89–96.CrossRefPubMed Yi HA, Kim MS, Jang SY, Lee YM, Ahn JH, Lee CH. Cellular signals involved in cyclooxygenase-2 expression induced by human cytomegalovirus. Virus Res. 2009;146:89–96.CrossRefPubMed
Metadata
Title
Relationship Between Cytomegalovirus Infection and Steroid Resistance in Inflammatory Bowel Disease: A Meta-Analysis
Authors
Xiao-wei Wu
Lin Wu
Hong-zan Ji
Fang-yu Wang
Publication date
01-11-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3733-6

Other articles of this Issue 11/2015

Digestive Diseases and Sciences 11/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.